PharmAbcine Inc. Logo

PharmAbcine Inc.

Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.

208340 | KO

Overview

Corporate Details

ISIN(s):
KR7208340000
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1689번길 70 KT대덕2연구센터 연구2동 2층, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PharmAbcine Inc. is a clinical-stage biotechnology company founded in 2008, specializing in the development of novel antibody therapeutics. The company leverages its proprietary fully human antibody library and discovery platforms to create next-generation, IgG-based monoclonal antibody (mAb) candidates. Its development pipeline focuses on treatments for cancer, neovascular eye diseases, and other vascular-related disorders. PharmAbcine's business model centers on advancing its therapeutic candidates through clinical trials with the objective of licensing them out to global partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Delisting Announcement
[기재정정]기타경영사항(자율공시) (상장폐지결정효력정지 가처분 신청)
Korean 12.1 KB
2025-08-19 00:00
Regulatory News Service
투자판단관련주요경영사항 (PMC-309 독점실시권 라이선스 계약(기술이전 계약))
Korean 10.0 KB
2025-08-19 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(자율공시:일정금액미만의청구) (위약벌청구의 소)
Korean 8.7 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-11 00:00
Legal Proceedings Report
소송등의판결ㆍ결정 (위약벌청구의 소)
Korean 5.0 KB
2025-05-28 00:00
Legal Proceedings Report
기타경영사항(자율공시) (상장폐지결정효력정지 가처분 신청)
Korean 6.3 KB
2025-05-28 00:00
Delisting Announcement
주권매매거래정지 (투자자보호)
Korean 4.6 KB
2025-05-28 00:00
Delisting Announcement
기타시장안내 (정리매매 보류 관련)
Korean 2.8 KB
2025-05-27 00:00
Delisting Announcement
기타시장안내 (코스닥시장위원회 심의·의결 결과 및 상장폐지 결정)
Korean 3.3 KB
2025-05-27 00:00
Delisting Announcement
주권매매거래정지해제 (상장폐지에 따른 정리매매 개시)
Korean 4.4 KB
2025-05-23 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.9 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 961.6 KB
2025-05-15 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 993.5 KB
2025-04-28 00:00
Regulatory News Service
기타시장안내 (개선계획 이행내역서 제출)
Korean 3.0 KB

Automate Your Workflow. Get a real-time feed of all PharmAbcine Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmAbcine Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmAbcine Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.